Sendai Virus Vector (Record no. 99095)

000 -LEADER
fixed length control field 03957nam a22004575i 4500
001 - CONTROL NUMBER
control field 978-4-431-54556-9
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220082927.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 140131s2013 ja | s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9784431545569
-- 978-4-431-54556-9
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-4-431-54556-9
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number QR355-502
072 #7 - SUBJECT CATEGORY CODE
Subject category code MMFM
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED052000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.9101
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Nagai, Yoshiyuki.
Relator term editor.
245 10 - TITLE STATEMENT
Title Sendai Virus Vector
Medium [electronic resource] :
Remainder of title Advantages and Applications /
Statement of responsibility, etc edited by Yoshiyuki Nagai.
264 #1 -
-- Tokyo :
-- Springer Japan :
-- Imprint: Springer,
-- 2013.
300 ## - PHYSICAL DESCRIPTION
Extent XII, 210 p. 33 illus., 17 illus. in color.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note 1. Reverse genetics of Mononegavirales: the rabies virus paradigm Karl-Klaus Conzelmann --   2. Sendai virus biology and engineering leading up to the development of a novel class of expression vector Yoshiyuki Nagai and Atsushi Kato --   3. Concept and technology underlying Sendai virus (SeV) vector development Akihiro Iida and Makoto Inoue --   4. Roadmap for development of a replication-deficient Sendai virus vaccine vector (provisional) Marian Wiegand and Wolfgang Neubert --   5. Development of vaccines using SeV vectors against AIDS and other infectious diseases Sayuri Seki and Tetsuro Matano --   6. BioKnife, a modified Sendai virus, to resect malignant tomors Yoshikazu Yonemitsu, Yasuji Ueda and Mamoru Hasegawa --   7. Induction of human pluripotent stem cells by the Sendai virus vector:Establishment of a highly efficient and foot-print free system Noemi Fusaki and Hiroshi Ban --   8. Gene therapy for peripheral arterial disease using Sendai virus vector: From preclinical Studies to the phase I/IIa clinical trial Yoshikazu Yonemitsu, Takuya Matsumoto and Yoshihiko Maehara.
520 ## - SUMMARY, ETC.
Summary, etc Sendai virus (SeV) is not just a mouse pathogen but is evolving into a cutting-edge component of biotechnology. SeV reverse genetics originating from a pure academic need to settle long-held questions in the biology and pathogenicity of nonsegmented negative strand RNA viruses (Mononegavirales) is about to bear the impressive fruit of multipurpose cytoplasmic (non-integrating) RNA vectors. This book brings together in one source the SeV biology revealed by conventional approaches and reverse genetics, the methods to construct the first-generation SeV vector and to generate safer versions, and the applications in medical settings that have left or are about to leave the laboratory bench. The applications, which already are diverse and have high medical impact, include use as vaccine vectors against AIDS and respiratory virus infections, creation of BioKnife to resect malignant tumors, induction of “footprint (transgene) free” pluripotent stem cells, and gene therapy for peripheral arterial disease. These achievements—which are just a few of many examples—were attainable only after rigorously incorporating the rich knowledge of SeV biology that has accumulated during the several decades since the discovery of the virus. Application of SeV vector is certain to expand greatly because of its extremely high performance in transgene expression and its remarkable target cell breadth.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Gene expression.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Gene therapy.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medical virology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Virology.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Gene Therapy.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Gene Expression.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9784431545552
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-4-431-54556-9
912 ## -
-- ZDB-2-SBL

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue